GlassScriptPhysician profile
Catalina Orozco
NPI 1306979141
$6,225.77
in general payments reported to CMS, 2019-2025
28 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $179 · 2021: $52.37 · 2022: $170 · 2023: $348 · 2024: $2,308 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,971 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.60 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,218.81 | 2019-2025 | |
| Amgen INC. | $874.38 | 2019-2025 | Otezla, Krystexxa, Enbrel |
| Pfizer INC. | $781.48 | 2019-2025 | |
| Ucb, INC. | $736.06 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $712.17 | 2019-2025 | |
| Janssen Biotech, INC. | $407.02 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $269.42 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $151.55 | 2019-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.88 | 2024-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $109.89 | 2024 | Saphnelo |
| Genzyme Corporation | $77.84 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $77.39 | 2024-2025 | Lupkynis |
| Octapharma USA, INC. | $69.70 | 2024 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $69.10 | 2025 | Tyenne |
| E.R. Squibb & Sons, L.L.C. | $63.74 | 2024-2025 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53.07 | 2025 | Acthar |
| Horizon Therapeutics Plc | $51.23 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $49.22 | 2024 | Arcalyst |
| Sobi, INC | $47.87 | 2019 | |
| Radius Health, INC. | $44.27 | 2024-2025 | Tymlos |
| Genentech USA, INC. | $44.19 | 2025 | Gazyva, Actemra |
| Ani Pharmaceuticals, INC. | $42.86 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Tonix Medicines, INC. | $38.83 | 2025 | Tonmya |
| Mallinckrodt Enterprises LLC | $28.09 | 2019 | |
| Hospira, INC. | $25.74 | 2024 | |
| Tersera Therapeutics LLC | $18.29 | 2025 | Quzyttir |
| Kyowa Kirin, INC. | $17.74 | 2025 | |
| Zimmer Biomet Holdings, INC. | $13.94 | 2024 | Gps III Platelet Concentration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catalina Orozco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.